Merck pharmaceuticals (MSD) inaugurates new research lab capacities in Lucerne, Switzerland

US-based biopharma giant expands its R&D site in Schachen

2023 June 21 – Merck & Co. ($59.3B revenue), a global research-intensive biopharmaceutical company headquartered in New Jersey, has newly expanded its research laboratories in Schachen (located in Canton Lucerne) to the tune of close to 20 Million Swissfrancs. Known as Merck Sharpe & Dohme or simply “MSD” in Europe, Merck & Co. employs over a thousand people throughout the region of Lucerne, Switzerland. 

The expanded Schachen biopharmaceutical laboratory will focus on the development of analytical methods for new active substances and medicines. The Schachen laboratory is one of only two worldwide, within Merck & Co.’s global network, which provides patients who are participating in clinical trials with new medicines. This research site now employs approximately 490 employees representing a diverse background of approximately 30 different countries.

Merck & Co. (“MSD” in Europe) has one of the largest clinical research programs worldwide; and the Swiss operations contribute around 40 clinical trials annually!